Cyclerion Therapeutics develops pharmacological treatments utilizing soluble guanylate cyclase (sGC) to target serious diseases associated with unmet medical needs. The company employs a strategic approach to drug development, leveraging cross-disciplinary expertise and collaborations to enhance patient access to its therapies.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Treatment-resistant depression (TRD) presents a significant challenge in mental healthcare, as conventional treatments often fail to provide adequate relief for affected individuals. The limitations of existing therapies highlight the urgent need for innovative approaches that can address the unique needs of patients with TRD.
Solution
Cyclerion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases, with an initial focus on treatment-resistant depression (TRD). The company is pursuing an individualized therapy for TRD, delivering generic intravenous anesthetics via a personalized delivery device that uses biofeedback for optimal safety and efficacy. This approach leverages well-established medicines with extensive safety data and cutting-edge technologies to enhance treatment precision. Cyclerion's strategy involves identifying and developing therapeutics that target neuropsychiatric disorders beyond conventional approaches, with the goal of bringing safe, effective, and accessible solutions to patients faster and at a lower cost.
Target Audience
The primary target audience includes individuals suffering from treatment-resistant depression (TRD) and the healthcare providers who treat them, including psychiatrists and other mental health professionals.
Features
- Personalized delivery device for intravenous anesthetics, utilizing biofeedback for safety and efficacy
- Focus on neuropsychiatric disorders, starting with treatment-resistant depression (TRD)
- Leveraging well-established medicines with extensive safety data
- Application of cutting-edge technologies to enhance treatment precision and effectiveness
- Option agreement to negotiate access to key intellectual property for TRD treatment